US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Accelerate Resources Limited (AX8) 銘柄情報

Accelerate Resources Limited (AX8)

0.005

0.00

(0.00%)

終了 6月29日 3:00PM

Accelerate Resources Limited (AX8) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.005

( - )

買値

0.005

売値

0.006

出来高

360,100

0.005 日の範囲 0.005

0.005 52 週間の範囲 0.009

時価総額

前日終値

0.005

始値

0.005

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 1,313,125

発行済株式数

1,011,188,712

配当利回り

PER

-7.68

1 株当たり利益 (EPS)

-0

歳入

17.79k

純利益

-535.9k

Accelerate Resources Limited operates as a mineral exploration company in Australia. The company explores for manganese, gold, lithium, and critical mineral deposits. Accelerate Resources Limited was incorporated in 2017 and is based in West Perth, Australia. Accelerate Resources Limited operates as a mineral exploration company in Australia. The company explores for manganese, gold, lithium, and critical mineral deposits. Accelerate Resources Limited was incorporated in 2017 and is based in West Perth, Australia.

セクター

Materials

業界

Mining

ウェブサイト

www.ax8.com.au

本社

West Perth, Australia

設立

2026

Accelerate Resources Limited is listed in the Materials sector of the オーストラリア証券取引所 with ticker AX8. The last closing price for Accelerate Resources was AUD0.01. Over the last year, Accelerate Resources shares have traded in a share price range of AUD 0.005 to AUD 0.009.

Accelerate Resources currently has 1,011,188,712 shares in issue. The market capitalisation of Accelerate Resources is AUD5.06 million. Accelerate Resources has a price to earnings ratio (PE ratio) of -7.68.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.001	-16.6666666667	0.006	0.006	0.005	723849	0.00514685	DE
4	-0.001	-16.6666666667	0.006	0.007	0.005	1634458	0.00529978	DE
12	-0.001	-16.6666666667	0.006	0.008	0.005	1047770	0.00576705	DE
26	-0.001	-16.6666666667	0.006	0.008	0.005	1255129	0.00640869	DE
52	-0.002	-28.5714285714	0.007	0.009	0.005	1157989	0.00680341	DE
156	-0.013	-72.2222222222	0.018	0.065	0.005	1363773	0.02479178	DE
260	-0.028	-84.8484848485	0.033	0.073	0.005	1203994	0.03001407	DE

AX8 - Frequently Asked Questions (FAQ)

What is the current Accelerate Resources Limited share price?

The current share price of Accelerate Resources Limited is AUD 0.005

How many Accelerate Resources Limited shares are in issue?

Accelerate Resources Limited has 1,011,188,712 shares in issue

What is the market cap of Accelerate Resources Limited?

The market capitalisation of Accelerate Resources Limited is AUD 5.06M

What is the 1 year trading range for Accelerate Resources Limited share price?

Accelerate Resources Limited has traded in the range of AUD 0.005 to AUD 0.009 during the past year

What is the PE ratio of Accelerate Resources Limited?

The price to earnings ratio of Accelerate Resources Limited is -7.68

What is the cash to sales ratio of Accelerate Resources Limited?

The cash to sales ratio of Accelerate Resources Limited is 284.25

What is the registered address of Accelerate Resources Limited?

The registered address for Accelerate Resources Limited is 16 Ord Street, West Perth, Western Australia, 6005

What is the Accelerate Resources Limited website address?

The website address for Accelerate Resources Limited is www.ax8.com.au

Which industry sector does Accelerate Resources Limited operate in?

Accelerate Resources Limited operates in the Mining sector

gdl

ONLY a breakdown in the DEAL seems a likely candidate for a CRASH. but it has to be decisive. TACO is not likely to bite unless his humiliation gest the better of him. I EXPECTED him to be FORCED to fight instead of signing such an embarrassing defeat deal. I was WRONG. But IRAN is pushing it for

Zardiw

#DDAmanda Chart on $TSLA.

Check our 4th of July Special! https://DDAmanda.com

https://DDAmanda.com/Charts/DDAmandaTSLA.jpg

#DDAmanda

Z

DewDiligence

DewDiligence 3分前

FDA sanity returning.

WizardSanctuary18

WizardSanctuary18 3分前

Thanks Kiwi👍

Eli's Gone

Eli's Gone 7分前

halldorson

halldorson 9分前

Interesting read -
Wall Street Peer ComparisonsTo gauge where a successful medical device company in this niche can trade, retail investors often look at peer companies targeting localized cancer therapies:Company / Asset ClassClinical StageTypical

Market Cap Visualized Equiv

CatfishHunter

CatfishHunter 9分前

Thanks for sharing the details on the Duke/Schaal ELP + I-131 work.

The 2022 Nature Biomedical Engineering paper showed impressive preclinical results in mouse pancreatic cancer models (strong tumor regression, especially combined with nanoparticle paclitaxel). That’s meaningful data

Seminole Red

Seminole Red 11分前

PEACHMAN

PEACHMAN 13分前

I suggest people read your informative IFUS post again so that it makes sense with my comments

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177740678

YOU stated

If I were the interim CEO of IFUS right now, what would I do? Let's just set

Whalatane

Whalatane 13分前

UNCY's UniSource hub .
I suggest you all read up on this B2B plan UNCY is starting to make it really easy for dialysis centers to prescribe , store and bill for OLC .
Its designed to over come a lot of the hurdles , drug co's face launching new drugs into a field dominated by Freseniu

Zadie420

Zadie420 15分前

Exactly eagle8.
I think once we use DCVax-L plus Poly-ICLC, DCVax-D+ and aDC1 treatments in other cancer types we will see tremendous price movement.

porty

Well, I don’t have my shares yet so they are worth nothing. More optimistic now that I might actually get them.

gorbec1

gorbec1 18分前

Let the piggy bank eat .

The excitement builds

OracleWitch66

OracleWitch66 19分前

You as well aqua

OracleWitch66

OracleWitch66 20分前

Hell yeah kj thanks for all your DD much appreciated let's go FITY

Musical Shares

Musical Shares 20分前

In over 25 years

It's quite a feature, isn't it?

What seems to always be missing here is that RadioGel was NOT the first thermogel with a radionuclide. It's even in their "prior art" section on their original patent from 1998!

And there have been many oth

eagle8

eagle8 21分前

starric, as usual, thanks for your posts.

The ultimate goal for NWBO is, of course, DCvax-Direct.
With the Kalinski method, aDCs, we won't need many adjuvants anymore.
Then only the companies with the most necessary adjuvants will benefit.
And there aren't that ma

barnstormer

barnstormer 21分前

Brazen. Boilerplate noise no, but boilerplate regardless. It's regulatory language the company has to keep repeating until the regulator approves the product. When I noted the language was also written to protect the company from litigation, I was referring to the whole regulatory document. Its car

3331

$250K IS THE MAGIC NUMBER!
$250,000 profit will get the PPS to COPPER @ P/E = 1,000 (not unusual for stocks turning profitable for the first time and with increasing future growth/revenue/profit projections). This will happen when investors are confident the profit will be achieved, likely

jimr1717

jimr1717 23分前

16 years of the same Ruse. No one is Fooled

Investor2014

Investor2014 25分前

Also carefully read section 2.6.9. Discussion on clinical safety.

That safety discussion is not comparable to a normal approved-drug safety review where risks are identified, quantified, labelled and managed. CHMP found that blarcamesine’s safety package was too small for a large chr

CanadianInvestor1

CanadianInvestor1 26分前

Check video out at 3:55 and 5:11.

CanadianInvestor1

CanadianInvestor1 28分前

New CEO took over 1.5 years ago. Lots of trial data in the last year shows the efficacy of Revyve. Recent video says this is a good time for entry to the US market, due to changes in Medicare rules last year pushing skin subs (competitors to KNBIF) out of business. https://wallstreetanalyzer.com/202

Accelerate Resources

Levler MSCI World ex US ...

iNAV DB XTRACKER DB Hedg...

AusNet Services Holdings...

Saxon Capital (ID)

Columbia Total Return Bo...

Great Portland Estates

Dorman Products

Jardine Cycle and Carriage (PK)

ProShares Morningstar Al...

Agf Equity Income Fund S...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。